NCT06190717ClinicalTrials.gov

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

En reclutamientoAdmite participantes ahora, según el registro.

Contactar con este estudio

En resumen

This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.

De intervención304 participantes buscados21 centros1 país

Categorías

Endocrino y metabólico48%Nefrología y urología44%Obstetricia y ginecología8%

Registrado en 1 registro

ClinicalTrials.govNCT06190717Abrir este registro en ClinicalTrials.govSincronizado hace 2 meses

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2024-01-05; recorded start 2024-02-21
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Sonavex, Inc.)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 2 conditions.
Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding0/20
Open-label
Control arm15/15
Active-comparator control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 21 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 304 participants (target), run at 21 sites.

How this score is built

Enrolment24/40
304 participants (target)
Site count16/25
21 sites
Country count0/15
Single country
Planned duration8/10
Planned over about 36 months
Sponsor scale0/10
Sonavex, Inc. has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

Afecciones

End Stage Renal Disease
Diabetes

Elegibilidad

Elegibilidad
Sexo	Todos
Edades	18 Years – 84 Years
Voluntarios sanos	No

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Males or non-pregnant, non-breastfeeding females ≥ 18 years of age but \< 85 years of age at the time of informed consent. * Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures. * Subject is willing and capable of complying with all required follow-up visits. * Subject and/or Care Team agree that the distance and transportation resources from the patient's home to the clinic are reasonable for study participation and compliance. * Subject has an estimated life expectancy \> 18 months. * Subject is ambulatory (cane or walker are acceptable). * CKD Stage 5 (eGFR less than 10) or ESRD subjects presenting for upper arm autologous arteriovenous fistula creation that is not transposed for hemodialysis access. * Subjects who are currently on dialysis through a CVC or who imminently require dialysis (GFR \<10). * Vein diameter ≥ 2.5 mm at the antecubital fossa per vein mapping. * Artery diameter ≥ 2.5 mm per vein mapping. * Subject is not participating in another investigational clinical trial that has not met its primary end point. Participation in post-market registry is acceptable. Exclusion Criteria: * CKD Stage 1-4 or subjects that do not require upper arm autologous arteriovenous fistula creation for hemodialysis access. * Subject has history of Steal Syndrome. * Subject who is immunocompromised or immunosuppressed. * Subject has had three previous failed AV fistulae for hemodialysis access. * Subjects expecting to undergo major surgery within 60 days from the EchoMark implantation. * Known or suspected active infection on the day of the index procedure. * Subjects who had infection(s) in the 30-day window prior to EchoMark placement to reduce the likelihood of partially treated infections that can seed the device and fistula. * Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count \<50,000), hypercoagulability, and history of recurrent deep vein thrombosis not related to AV access. * Subjects with active malignancy. * Subjects with a history of poor compliance with the dialysis protocol. * Subjects with a known or suspected allergy to any of the device materials. * Subjects with an existing fistula or graft. * Subjects who are anticipated to convert to peritoneal dialysis or undergo a transplant within 6 months. * Subjects who are pregnant, planning on becoming pregnant, or are breast feeding.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudio	De intervención
Fase	No aplicable
Asignación	Aleatorizado
Modelo de intervención	PARALLEL
Propósito principal	TREATMENT
Enmascaramiento	NONE (0)
Inscripción	304 participantes buscados

Patrocinador y colaboradores

Sonavex, Inc. Patrocinador

Grupos e intervenciones

Diagnostic ArmEXPERIMENTAL
All subjects will have the EchoMark implanted. Subjects will be assessed every 2 weeks (+/- 1 week) (but no more frequently than weekly) with the EchoSure system until fistula maturation occurs and/or permanent access use is achieved.
Standard of CareACTIVE_COMPARATOR
Subjects will be evaluated per KDOQI guidelines (with physical examination at approximately 2 weeks (+/- 1 week) and between 4 and 6 weeks (+/- 1 week)). If evaluation yields abnormal findings, subjects will receive a Duplex ultrasound assessment (DUS). All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.

Intervenciones

Dispositivo EchoMark/EchoSure
Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
Procedimiento Standard of Care
Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.

Variables de resultado

Variable de resultado principal
Primary Safety Endpoint
Freedom from the following through 6 months as adjudicated by the CEC: 1. Clinically significant misplacement or migration of the EchoMark implant. 2. Vessel or tissue injury caused by the EchoMark implant procedure of the implant over time, requiring surgical intervention. 3. Infection of tissues surrounding the EchoMark implant requiring IV/ 4. Complication requiring explantation of the EchoMark implant.
Plazo 6 months
Variable de resultado principal
Primary Effectiveness Endpoint
Time to clinical maturation
Plazo 6 months
Variable de resultado secundaria
Difference between EchoSure and Duplex Flow Measurements
Difference between log10-transformed EchoSure and Duplex flow measurements of blood flow for assessment of measurement agreement in the diagnostic arm.
Plazo 6 Months
Variable de resultado secundaria
EchoSure Depth Comparison
Difference between EchoSure and CoreLab measurements of depth for assessment of measurement agreement in the diagnostic arm.
Plazo 6 Months
Variable de resultado secundaria
EchoSure Diameter Comparison
Difference between EchoSure and CoreLab measurement of diameter for assessment of measurement agreement in the diagnostic arm.
Plazo 6 Months
Variable de resultado secundaria
EchoMark/EchoSure System Technical Success
Technical Success defined as the successful implantation of the EchoMark implant and the ability to complete each scan to determine the blood flow, diameter, and depth measurements at the EchoMark using the EchoSure diagnostic ultrasound system from baseline to Clinical Maturation, fistula failure, or 4 months, whichever is sooner.
Plazo 4 Months
Variable de resultado secundaria
CVC Removal
Time to CVC removal by subject group
Plazo 6 Months
Variable de resultado secundaria
Rate of Hospitalization
Rate of hospitalization(s) by subject group from baseline to Clinical Maturation.
Plazo 6 Months
Variable de resultado secundaria
AV Fistula Maturation Rate
Percent of AVFs created that mature by 180 days by subject group.
Plazo 6 Months
Variable de resultado secundaria
Total Cost of Care
Total cost of care, defined by National average Medicare payment rate (facility and professional fees) for procedures and care provided to subject by subject group from baseline to Clinical Maturation.
Plazo 6 Months
Variable de resultado secundaria
Freedom from Events through 30 and 90 Days
Freedom from the following through 30 and 90 days from the baseline procedure as adjudicated by the CEC: 1. Clinically significant misplacement or migration of the EchoMark implant. 2. Vessel or tissue injury caused by the EchoMark implant procedure of the implant over time, requiring surgical intervention. 3. Infection of tissues surrounding the EchoMark implant requiring IV antibiotic treatment. 4. Complication requiring explantation of the EchoMark implant.
Plazo 30 Days and 90 Days
Otra variable de resultado
Hierarchical Composite 1
Hierarchical composite of the DIAG arm and SOC arm comparing occurrences of: Fistula creation success.
Plazo 6 Months
Otra variable de resultado
Hierarchical Composite 2
Hierarchical composite of the DIAG arm and SOC arm comparing occurrences of: Alive through 180 days.
Plazo 6 Months
Otra variable de resultado
Hierarchical Composite 3
Hierarchical composite of the DIAG arm and SOC arm comparing occurrences of: Freedom from SAE with 180 days (severity as a tie-breaker for SAEs with matching adverse event term)
Plazo 6 Months
Otra variable de resultado
Hierarchical Composite 4
Hierarchical composite of the DIAG arm and SOC arm comparing occurrences of: Earlier time to AV fistula Clinical Maturation with 180 days.
Plazo 6 Months
Otra variable de resultado
Comparison of Composite and Stratified MAE Rates
Comparison of composite and stratified MAE rates for both subject groups at 6 months and end of study. MAEs are adjudicated by the CEC and defined as any of the following: 1. Clinically significant misplacement or migration of the EchoMark implant. 2. Vessel or tissue injury caused by the EchoMark implant procedure or the implant over time, requiring surgical intervention. 3. Complication requiring explantation of the EchoMark implant. 4. Clinically significant surgical complications (seroma, edema, hematoma, bleeding), excluding expected resorption response visible as hypoechoic region on B-mode ultrasound. 5. Infection requiring IV antibiotic treatment. Pseudoaneurysm. 6. Thrombosis of the AVF circuit that requires an intervention (surgical or endovascular). 7. Steal Syndrome.
Plazo 6 Months and 12 Months
Otra variable de resultado
Comparision of Implant and Procedure Related Adverse Events
Comparison of all stratified implant and procedure related AE (as adjudicated by the CEC) rates between subject groups at 6 months and end of study.
Plazo 6 Months and 12 Months
Otra variable de resultado
Clinical Maturation
Percent of subjects that have reached Clinical Maturation (as adjudicated by the CEC) for each subject group at 90 days, 120 day, 150 days, and 180 days.
Plazo 3 Months, 4 Months, 5 Months, and 6 Months
Otra variable de resultado
Cannulation Complication Rates
Comparison of composite and stratified cannulation complication (as adjudicated by the CEC) rates between subject groups for the following AEs: 1. Infection due to cannulation. 2. Thrombosis due to hematoma. 3. Any other AE determined by the CEC to be cannulation related.
Plazo 12 Months
Otra variable de resultado
Time to Clinical Maturation for Procedure and Device Related Events
Distribution of time to Clinical Maturation for both groups for each of the following procedure and device related categories presented as violin/box plots: 1. Clinically significant misplacement or migration of the EchoMark implant. 2. Vessel or tissue injury caused by the EchoMark implant procedure or the implant over time, requiring surgical intervention. 3. Clinically significant surgical complications (seroma, edema, hematoma, bleeding), excluding expected resorption response visible as hypoechoic region on B-mode ultrasound. 4. Infection requiring IV antibiotic treatment. 5. Pseudoaneurysm. 6. Thrombosis of AVF circuit requiring an intervention (surgical or endovascular). 7. Steal Syndrome. 8. No SAE.
Plazo 6 Months
Otra variable de resultado
Primary Functional Patency
Primary functional patency at 6 months (as adjudicated by the CEC) defined as freedom from intervention on the AVF after maturation.
Plazo 6 Months
Otra variable de resultado
Secondary Function Patency
Secondary functional patency at 6 months (as adjudicated by the CEC) is defined as freedom from abandonment of the AVF after maturation.
Plazo 6 Months
Otra variable de resultado
Time to Clinical Maturation
Time to Clinical Maturation (as adjudicated by the CEC) defined as the time from initial fistula creation to Clinical Maturation.
Plazo 6 Months
Otra variable de resultado
Time to Clinical Maturation for Each Fistula
Time to Clinical Maturation (as adjudicated by the CEC) for each new fistula defined as the time from new fistula creation to Clinical Maturation.
Plazo 6 Months
Otra variable de resultado
Technical Success Cannulation Scans
Rate of cannulation zone technical success rate defined as the ability to complete each scan to determine the diameter, and depth measurements at the proximal, mid, and distal segments of the fistula using the EchoSure diagnostic ultrasound system from the 2-week follow-up to Clinical Maturation, or 4 months, whichever is sooner.
Plazo 4 Months
Otra variable de resultado
EchoSure Diameter and Depth Comparison in Cannulation Zone
Agreement of EchoSure diameter and depth results from the cannulation zone at the 6-week follow-up compared to the CoreLab measured diameter and depth results in the DIAG arm.
Plazo 6 Months
Otra variable de resultado
Intervention to Assist Maturation Rate
Surgical or Endovascular Interventions to Assist Maturation defined as the difference between groups in the proportion of subjects with surgical or endovascular interventions to assist maturation.
Plazo 6 Months

Fechas

Fechas
Fecha de inicio	21 de febrero de 2024 (real)
Finalización principal	1 de febrero de 2027 (estimada)
Finalización	1 de febrero de 2027 (estimada)
Primera publicación	5 de enero de 2024 (real)
Última actualización	13 de abril de 2026
Resultados publicados	No indicado en el registro
Estado verificado por última vez	junio de 2025

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

20 centros están en reclutamiento

United States

United States
Centro	Ciudad	Estado o región	Estado
HealthQare Associates	Arlington	Virginia	En reclutamiento
Boston Medical Center	Boston	Massachusetts	En reclutamiento
Galen Medical Group	Chattanooga	Tennessee	En reclutamiento
Northwestern University	Chicago	Illinois	En reclutamiento
Atrium Health	Concord	North Carolina	En reclutamiento
Baylor Scott & White Heart and Vascular Hospital	Dallas	Texas	En reclutamiento
Trinity Research Group	Dothan	Alabama	En reclutamiento
Prisma Health	Greenville	South Carolina	En reclutamiento
Aqua Research Institute Llc	Houston	Texas	En reclutamiento
MSU Health Care Heart and Vascular	Lansing	Michigan	En reclutamiento
Fresenius Vascular Care Memphis MSO	Memphis	Tennessee	Finalizado antes de tiempo
Northwell Health	New Hyde Park	New York	En reclutamiento
Medical University of South Carolina Health Orangeburg	Orangeburg	South Carolina	En reclutamiento
Orlando Health Heart and Vascular Institute	Orlando	Florida	En reclutamiento
Capital Medical Center	Pennington	New Jersey	En reclutamiento
Southwest Kidney Institute	Phoenix	Arizona	En reclutamiento
AKDHC Medical Research Services	Phoenix	Arizona	En reclutamiento
Physicians Care of Virginia	Roanoke	Virginia	En reclutamiento
AKDHC Center Tucson	Tucson	Arizona	En reclutamiento
Sentara Health	Virginia Beach	Virginia	En reclutamiento
Kansas Nephrology Research Institute	Wichita	Kansas	En reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

No se han registrado cambios desde que incorporamos este registro por primera vez.

Se registra un cambio cada vez que el patrocinador actualiza el registro. El estado, las fechas, la inscripción y los centros aparecen aquí a medida que cambian.

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06190717